Revolution MedicinesRVMD
About: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Employees: 490
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
104% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 27
44% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 63
16% more capital invested
Capital invested by funds: $6.62B [Q2] → $7.66B (+$1.04B) [Q3]
13% more funds holding
Funds holding: 220 [Q2] → 248 (+28) [Q3]
6% more funds holding in top 10
Funds holding in top 10: 18 [Q2] → 19 (+1) [Q3]
2.3% less ownership
Funds ownership: 103.39% [Q2] → 101.09% (-2.3%) [Q3]
58% less call options, than puts
Call options by funds: $11.8M | Put options by funds: $28.1M
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
Needham Ami Fadia 61% 1-year accuracy 93 / 152 met price target | 23%upside $68 | Buy Maintained | 7 Nov 2024 |
HC Wainwright & Co. Robert Burns 43% 1-year accuracy 69 / 161 met price target | 16%upside $64 | Buy Maintained | 7 Nov 2024 |
JP Morgan Eric Joseph 72% 1-year accuracy 18 / 25 met price target | 14%upside $63 | Overweight Maintained | 7 Nov 2024 |
Piper Sandler Joseph Catanzaro 45% 1-year accuracy 14 / 31 met price target | 27%upside $70 | Overweight Maintained | 7 Nov 2024 |
Guggenheim Michael Schmitz 80% 1-year accuracy 4 / 5 met price target | 49%upside $82 | Buy Maintained | 28 Oct 2024 |
Financial journalist opinion
Based on 7 articles about RVMD published over the past 30 days
